JSPR241018P12500
- 1.87
- 0.000.00%
Jasper Therapeutics Newsroom
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
Jasper Therapeutics Analyst Ratings
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
Buy Rating Affirmed for Jasper Therapeutics Amid Promising Briquilimab Prospects and Strategic Development
BTIG Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $90
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
JMP Securities Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $70
Jasper Therapeutics Price Target Maintained With a $65.00/Share by Evercore ISI Group
Jasper Therapeutics Analyst Ratings
Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Maintains $65 Price Target
Jasper Therapeutics (JSPR) Gets a Buy From Stifel Nicolaus
Jasper Therapeutics Price Target Cut to $68.00/Share From $70.00 by RBC Capital
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Cuts Target Price to $68
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $55 to $90
RBC Capital Keeps Their Buy Rating on Jasper Therapeutics (JSPR)
Buy Rating Reaffirmed for Jasper Therapeutics on Strong Clinical Performance and Market Potential
Jasper Therapeutics Analyst Ratings